STAT

Opinion: Synthetic control arms can save time and money in clinical trials

Synthetic control arms aren't the solution to all of the challenges facing randomized trials, but they represent a great way for drug development companies to start using real-world evidence.

Among the many vexing issues faced by companies that conduct clinical trials, at least two of them — the large number of participants needed for trials and participants’ fears they will be end up getting a placebo — can be eased by using an innovative approach to collecting comparison data called synthetic control arms.

With the skyrocketing cost of clinical trials, the proliferation of digital data, and a new FDA commitment to considering real-world data in regulatory decision making, it’s the right time to begin using synthetic control arms. Medical product development is at the brink of a new age of evidence generation, an environment that’s ripe for disruption. The next step requires risk taking, not something this industry is known for.

Synthetic control arms

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS Under Investor Pressure, A Final Warning To J&J And More
Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of deadlines, online meetings and phone calls…
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Pfizer Struggles With Starboard, Lilly Going After Compounders, And More
Two former Pfizer executives said they will not be involved with activist investor Starboard Value
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Pfizer And Its Activist Investor, Medicare Costs For Obesity Drugs, And More
Authorizing Medicare to cover weight loss drugs would increase federal spending by about $35 billion from 2026 to 2034

Related Books & Audiobooks